$PMCB Promising Diabetes Treatment Using Human Liver Cells May Be on the Horizon
JUNE 6, 2016 Katie McCallumBY KATIE MCCALLUM IN NEWS.
A collaboration between Prof. Ann Simpson of the University of Technology Sydney (UTS) in Australia and a U.S. clinical stage biotechnology company, PharmaCyte Biotech, shows promise for a unique alternative therapy for a generation of type 1 diabetes patients.
Utilizing human liver cells engineered to supply the body with insulin, the therapy could eliminate the daily requirements for insulin management and prevent life threatening complications associated with diabetes.
In 2012 it was estimated that diabetes affects 29.1 million people worldwide. The Juvenile Diabetes Research Foundation estimates that 3 million Americans alone suffer from the autoimmune disease type 1 diabetes, for which there is currently no cure. The current treatment of type 1 diabetes requires frequent insulin injections and dietary restrictions. More seriously, type 1 diabetes is a lifelong autoimmune disease that can ultimately result in eye and kidney diseases, nerve impairment, and cardiovascular complications.
Simpson and her colleagues developed insulin-producing, artificially engineered “Melligen” cells that produce, store, and release insulin in amounts relevant to the blood sugar levels of individual patients. A patent was recently obtained for Melligen cells through the U.S. Patent Office, and the cell line is now in the process of being commercialized for human preclinical trials by PharmaCyte.
PharmaCyte’s Cell-in-a-Box technology will be used to prevent the inflammatory immune response that commonly happens upon transplantation of foreign tissue into the body. Cell-in-a-Box is a signature technology of PharmaCyte and serves to encapsulate live cells in a robust manner for an extended time to aid in successful transplantation. PharmaCyte hopes to apply this technology to Melligen cells to ensure their success in the human body.
Using the insulin-producing Melligen cells developed at UTS, along with PharmaCyte’s advanced biological delivery technology Cell-in-a-Box, researchers hope to commercialize a groundbreaking therapy as they work toward a possible cure for type 1 diabetes. Melligen cells could also be used in cases of advanced type 2 diabetes, where current medications are no longer effective.
“For the millions of people worldwide who suffer from a disease of epidemic proportions, our treatment could relieve them of the onerous daily requirements for insulin administration and dietary restrictions and offer a life free from the very serious and even life-threatening complications associated with diabetes,” said PharmaCyte CEO Kenneth L. Waggoner.
Katie McCallum is a PhD candidate at University of Texas Health Science Center at Houston in the Microbiology and Molecular Genetics program. While at the bench, her research is primarily focused on the basic biology governing host-microbial interactions. Katie's research interests extend far beyond the scope of medical microbiology. Her exposure to the enormity of collaborative effort and innovative research that exists in the Texas Medical Center has fostered her interest in science communication and science outreach.
Of course "plans" for trials are still on. They've been on since pmcb acquired the license. If they said trials are off what do you suppose would happen to the PPS? No Kenny boy will never say trials are not happening. That would be devastating to his income. Instead he'll just keep announcing every little step up the ladder with out ever taking the dive. Pmcb will continue stringing investors along eventually loosing the confidence of even the most faithful.
I'm sure this is common knowledge for you and few others but I guarantee its not for everyone. You said you know the risk is extremely high here and are just betting what you can afford to loose with the chance of hitting a jackpot. I say good luck. Better odds in the state lotto though.
News 
Market Data 
Discover 
